Abstract-The angiotensin II (Ang II) type 1 (AT 1 ) receptor mainly mediates the physiological and pathological actions of Ang II, but recent studies have suggested that AT 1 receptor inherently shows spontaneous constitutive activity even in the absence of Ang II in culture cells. To elucidate the role of Ang II-independent AT 1 receptor activation in the pathogenesis of cardiac remodeling, we generated transgenic mice overexpressing AT 1 receptor under the control of ␣-myosin heavy chain promoter in angiotensinogen-knockout background (AT 1 Tg-AgtKO mice). In AT 1 Tg-AgtKO hearts, redistributions of the G␣ q11 subunit into cytosol and phosphorylation of extracellular signal-regulated kinases were significantly increased, compared with angiotensinogen-knockout mice hearts, suggesting that the AT 1 receptor is constitutively activated independent of Ang II. As a consequence, AT 1 Tg-AgtKO mice showed spontaneous systolic dysfunction and chamber dilatation, accompanied by severe interstitial fibrosis. Progression of cardiac remodeling in AT 1 Tg-AgtKO mice was prevented by treatment with candesartan, an inverse agonist for the AT 1 receptor, but not by its derivative candesartan-7H, deficient of inverse agonism attributed to a lack of the carboxyl group at the benzimidazole ring. Our results demonstrate that constitutive activity of the AT 1 receptor under basal conditions contributes to the cardiac remodeling even in the absence of Ang II, when the AT 1 receptor is upregulated in the heart. (Hypertension. 2012;59:627-633.) • Online Data Supplement Key Words: ARB Ⅲ cardiac dysfunction Ⅲ fibrosis Ⅲ G protein-coupled receptor Ⅲ inverse agonist T he angiotensin II (Ang II) type 1 (AT 1 ) receptor is a 7 transmembrane spanning G protein-coupled receptor (GPCR), and the activation of AT 1 receptor is involved in regulating pathophysiological processes of the cardiovascular system. In principle, the AT 1 receptor is activated on binding to Ang II, which is produced systemically or locally after sequential proteolytic processing. However, recent studies demonstrated that the AT 1 receptor inherently shows spontaneous constitutive activity even in the absence of Ang II in cultured cells. [1][2][3] GPCRs are structurally unstable and show significant levels of spontaneous activity in an agonistindependent manner. 4 In addition, we and others demonstrated that the AT 1 receptor can be activated by mechanical stress independent of Ang II 5-7 through conformational switch of the receptor. 1 These observations have highlighted the inverse agonist activity of AT 1 receptor blockers (ARBs) as a drug-specific property that can inhibit Ang II-independent constitutive activity and mechanical stress-induced receptor activation. 1,2,5, 8 In a mouse model, mechanical stressinduced AT 1 receptor activation led to the development of cardiac hypertrophy independent of Ang II, and treatment with inverse agonists for the AT 1 receptor-attenuated cardiac hypertrophy thus formed. 5 However, the pathogenic role of Ang II-independent constitutive activity of the AT 1 receptor and clinical relevance of inverse agonist activity of ARBs against constitutive receptor activation remains to be elucidated in vivo. In several GPCRs, gain-of-function mutations are causative of diseases, but any activating mutations in the 
T he angiotensin II (Ang II) type 1 (AT 1 ) receptor is a 7 transmembrane spanning G protein-coupled receptor (GPCR), and the activation of AT 1 receptor is involved in regulating pathophysiological processes of the cardiovascular system. In principle, the AT 1 receptor is activated on binding to Ang II, which is produced systemically or locally after sequential proteolytic processing. However, recent studies demonstrated that the AT 1 receptor inherently shows spontaneous constitutive activity even in the absence of Ang II in cultured cells. [1] [2] [3] GPCRs are structurally unstable and show significant levels of spontaneous activity in an agonistindependent manner. 4 In addition, we and others demonstrated that the AT 1 receptor can be activated by mechanical stress independent of Ang II [5] [6] [7] through conformational switch of the receptor. 1 These observations have highlighted the inverse agonist activity of AT 1 receptor blockers (ARBs) as a drug-specific property that can inhibit Ang II-independent constitutive activity and mechanical stress-induced receptor activation. 1, 2, 5, 8 In a mouse model, mechanical stressinduced AT 1 receptor activation led to the development of cardiac hypertrophy independent of Ang II, and treatment with inverse agonists for the AT 1 receptor-attenuated cardiac hypertrophy thus formed. 5 However, the pathogenic role of Ang II-independent constitutive activity of the AT 1 receptor and clinical relevance of inverse agonist activity of ARBs against constitutive receptor activation remains to be elucidated in vivo. In several GPCRs, gain-of-function mutations are causative of diseases, but any activating mutations in the coding region of the AT 1 receptor gene have not been identified in hypertension or primary hyperaldosteronism. 9, 10 Although knock-in mice with a constitutively activating mutation (substitution of Asn 111 to Ser with a C-terminal deletion) showed low-renin hypertension and progressive fibrosis in kidney and heart, 11 it remains unclear whether constitutive activity of the native AT 1 receptor leads to some phenotypic abnormalities even under circumstances where the production of Ang II is genetically inhibited.
Therefore, we generated transgenic mice overexpressing AT 1 receptor under the control of ␣-myosin heavy chain promoter in the angiotensinogen (Agt)-knockout background. Here, we show that constitutive activity of the AT 1 receptor indeed contributes to cardiac remodeling independent of Ang II even in vivo, when the AT 1 receptor is upregulated in the heart.
Methods
An expanded Methods section is available in the online-only Data Supplement.
Mice, Transverse Aortic Constriction Operation, and Transthoracic Echocardiography
Mice expressing the human AGTR1 gene under the control of ␣-myosin heavy chain promoter (on the C57BL/6J background) and mice deficient for the Agt gene (on the Institute of Cancer Research [ICR] background) were described previously. 12, 13 Candesartan cilexetil and candesartan-7H were synthesized by Takeda Pharmaceutical Co, Ltd, and administered via drinking water. Sham or transverse aortic constriction operation was performed as described previously, 5 and transthoracic echocardiography was performed on conscious mice with a Vevo 770 Imaging System. All of the protocols were approved by the institutional animal care and use committee of Chiba University.
Ang II Infusion and BP Measurement
Eight-week-old C57BL/6J male mice were treated with Ang II (0.6 mg/kg per day) or vehicle for 2 weeks using an osmotic mini-pump (ALZET model 2002; Durent Corp). The BP and pulse rates were measured noninvasively by a programmable sphygmomanometer (BP-98A, Softron) using the tail-cuff method.
Real-Time RT-PCR Analysis
Total RNA was extracted by using the RNeasy kit (Qiagen), and single-stranded cDNA was transcribed by using QuantiTect Reverse Transcription kit (Qiagen), according to the manufacturer's protocol. We conducted quantitative real-time PCR analysis with the Universal ProbeLibrary Assays (Roche Applied Science), according to the manufacturer's instructions.
Western Blot Analysis and Histological Analysis
Western blot analysis and histological were performed as described previously. 1, 5 
Radioligand Receptor Binding Assay
Radioligand binding assays were performed as described previously. 1, 14 
Statistics
All of the data are presented as meanϮSEM. Two-group comparison was analyzed by unpaired 2-tailed Student t test, and multiple-group comparison was performed by 1-way ANOVA followed by the Fisher protected least significant difference test for comparison of means. A P value of PϽ0.05 was considered to be statistically significant.
Results

AT 1 Receptor Is Constitutively Activated Without the Involvement of Ang II in AT 1 Transgenic-Angiotensinogen Knockout Mice Hearts
To elucidate the pathogenic role of Ang II-independent AT 1 receptor activation in the hearts, we crossed transgenic mice overexpressing human AT 1 receptor under the control of cardiac-specific ␣-myosin heavy chain promoter (AT 1 Tg) with angiotensinogen knockout mice (AgtKO) to generate AT 1 Tg-AgtKO mice. First, we examined the expression levels of renin-angiotensin system components. Although the mRNA level of the AT 2 receptor (Agtr2) was significantly higher in AT 1 Tg-AgtKO hearts than in AgtKO hearts, there was no significant difference in protein levels of the AT 2 receptor between AT 1 Tg-AgtKO and AgtKO hearts ( Figure  S1 in the online-only Data Supplement). Furthermore, the mRNA levels of the AT 1b receptor (Agtr1b), angiotensinconverting enzyme (Ace), and renin (Ren1 and Ren2) did not differ significantly between AT 1 Tg-AgtKO and AgtKO hearts ( Figure S1A ).
We 1 Tg-AgtKO hearts, we examined redistribution of G␣ q11 into the cytosolic fraction and phosphorylation of extracellular signal-regulated kinases (ERKs) in AgtKO and AT 1 TgAgtKO hearts. On activation of the AT 1 receptor, the heterotrimeric G q protein dissociates into ␣ and ␤␥ subunits, and the GTP-bound G␣ q subunit stimulates diverse intracellular signaling pathways, including the ERK pathway. 15, 16 Redistribution of G␣ q11 subunits from the particulate to the cytosolic fraction was significantly increased in AT 1 TgAgtKO hearts compared with AgtKO hearts ( Figure 1A ). In addition, the levels of phosphorylated ERKs in AT 1 TgAgtKO hearts was significantly increased compared with AgtKO hearts ( Figure 1B) . These results suggest that the AT 1 receptor is upregulated and constitutively activated without the involvement of Ang II in the AT 1 Tg-AgtKO hearts.
AT 1 Tg-AgtKO Mice Display Progressive Cardiac Remodeling
Tail-cuff measurements of systolic and diastolic blood pressure (BPs) and pulse rates revealed that these parameters did not differ significantly between AgtKO and AT 1 Tg-AgtKO mice at 20 weeks of age (Table) . However, morphological and physiological analysis revealed progressive chamber dilatation, contractile dysfunction, and interstitial fibrosis in AT 1 Tg-AgtKO mice, whereas cardiac structure and function were normal in AgtKO mice. At 20 weeks of age, AT 1 TgAgtKO mice displayed Ϸ1.5-fold increase in heart:body weight ratio compared with AgtKO mice (Table) . Echocardiographic examination revealed a progressive increase in left ventricular end-diastolic dimension and decrease in the percentage of fractional shortening ( Figure 2A ). Histologically, a significant increase in interstitial fibrosis was observed in AT 1 Tg-AgtKO mice at 20 weeks of age and further exacerbated at 36 weeks of age ( Figure 2B ). Furthermore, real-time RT-PCR indicated that mRNA levels of fetal cardiac genes (Nppa, Nppb, and Acta1) and extracellular matrix genes (Col3a1 and Postn) were significantly increased in AT 1 Tg-AgtKO hearts compared with AgtKO hearts ( Figure 2C ). These results indicate that upregulation of the AT 1 receptor induced spontaneous and progressive cardiac remodeling in AT 1 Tg-AgtKO mice in spite of systemic deficiency of Ang II.
Cardiac Remodeling in AT 1 Tg-AgtKO Mice Is Prevented by Treatment With an Inverse Agonist for the AT 1 Receptor
We examined whether an AT 1 receptor blocker candesartan could prevent the progression of cardiac remodeling in AT 1 Tg-AgtKO mice. In cultured cells, candesartan reduces the basal activity of both the wild-type AT 1 receptor and constitutively active AT 1 mutant receptors, suggesting that candesartan is an inverse agonist for the AT 1 receptor. 1 Candesartan also suppresses mechanical stretch-induced helical movement and thereby inhibits receptor activation 1 and prevents pressure-overload cardiac hypertrophy in mice. 5 Tail-cuff measurements revealed a significant increase in systolic BP in 8-week-old C57BL/6 male mice treated with Ang II (0.6 mg/kg per day) for 2 weeks using an osmotic minipump ( Figure 3A ). This BP elevation was abolished by treatment with candesartan cilexetil (1 mg/kg per day) in drinking water. Candesartan cilexetil is a prodrug that is converted rapidly and completely to candesartan during gastrointestinal absorption. 17 Interestingly, treatment with candesartan cilexetil prevented the progression of cardiac remodeling in AT 1 Tg-AgtKO mice, when treatment was initiated at 6 weeks of age. The increases in heart:body weight ratio ( Figure 3B ), chamber dilatation and contractile dysfunction ( Figure 3C ), and interstitial fibrosis ( Figure 3D ) were significantly attenuated by candesartan cilexetil. Consistently, real-time RT-PCR indicated that the increases in mRNA levels of fetal cardiac genes (Nppa, Nppb, and Acta1) and extracellular matrix genes (Col3a1 and Postn) in AT 1 TgAgtKO hearts were significantly attenuated by treatment with candesartan cilexetil ( Figure 3E ).
We reported previously that tight binding between the carboxyl group of candesartan and specific residues of the AT 1 receptor was critical for the potent inverse agonism and that a derivative of candesartan (candesartan-7H), lacking the carboxyl group at the benzimidazole ring, could not suppress agonist-independent activities of the receptor. 1 Although treatment with candesartan-7H (1 mg/kg per day) had no effect, treatment with candesartan-7H (20 mg/kg per day) suppressed Ang II-induced BP elevation in C57BL/6 male mice, almost equally as treatment with candesartan cilexetil (1 mg/kg per day) did. ( Figure 3A ). However, treatment with candesartan-7H (20 mg/kg per day) did not prevent the increase in heart:body weight ratio ( Figure 3B ), progression of chamber dilatation, contractile dysfunction ( Figure 3C ), interstitial fibrosis ( Figure 3D ), or the increase in mRNA levels of fetal cardiac genes and extracellular matrix genes in AT 1 Tg-AgtKO mice. Tail because Ang II is not produced in AT 1 Tg-AgtKO mice. Collectively, these results suggest that cardiac remodeling in AT 1 Tg-AgtKO mice was prevented by candesartan, an inverse agonist for the AT 1 receptor, but not by candesartan-7H, which cannot inhibit Ang II-independent AT 1 receptor activation because of a lack of inverse agonist activity.
Discussion
In several GPCRs, the constitutive activity is closely related to physiological function. For example, constitutive activity of the histamine H 3 receptor controls histaminergic neuron activity in rodents. 18 The melanocortin-4 receptor and growth hormone secretagogue receptor have high constitutive activity, and loss of constitutive activity in mutant melanocortin-4 receptors or growth hormone secretagogue receptors leads to obesity or short stature in humans, respectively. 19, 20 In contrast, constitutively active mutations in several GPCRs give rise to diseases in humans. For example, somatic mutations of thyrotropin-stimulating hormone receptor or luteinizing hormone receptor lead to hyperfunctioning thyroid adenoma or male precocious puberty, respectively. 21, 22 In the present work, we provide experimental evidence that transgenic myocardial overexpression of the wild-type AT 1 receptor increases constitutive activity of the receptor, leading to cardiac enlargement, interstitial fibrosis, and contractile dysfunction, even in the absence of Ang II. To exclude a 
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contribution of endogenous Ang II to the activity of AT 1 receptor in native tissues, we used AgtKO mice, deficient in the production of Ang II. 13 Furthermore, AT 1 Tg-AgtKO mice developed cardiac remodeling regardless of whether they were the offspring of Agt ϩ/Ϫ females or Agt Ϫ/Ϫ females ( Figure S3 ), suggesting that maternal or placental angiotensinogen had little influence on the postnatal development of cardiac remodeling in AT 1 Tg-AgtKO mice. Among the renin-angiotensin system components, the mRNA level of the AT 2 receptor was significantly upregulated in AT 1 Tg-AgtKO hearts compared with AgtKO hearts (Figure S1A) , but the protein level of the AT 2 receptor was comparable between AT 1 Tg-AgtKO and AgtKO hearts. Therefore, we believe that constitutive activity of the AT 1 receptor is sufficient for inducing structural and functional cardiac remodeling, when the AT 1 receptor is upregulated in the hearts.
Redistribution of G␣ q11 into the cytosolic fraction in AT 1 Tg-AgtKO hearts ( Figure 1A) indicates that constitutive activity of the AT 1 receptor is mediated through the G␣ q11 -dependent signaling pathway. On binding to Ang II, the AT 1 receptor is phosphorylated by GPCR kinases and recruits ␤-arrestins, leading to clathrin-coated, pit-dependent internalization and then recycling to the plasma membrane. 23 It has been reported that constitutively active mutant AT 1 receptors are constitutively internalized and recycled when overexpressed in HEK293 cells. 24 In contrast, we showed previously, by immunofluorescence analysis, that the wild-type AT 1 receptor was predominantly localized in the plasma membrane of HEK293 cells expressing the AT 1 receptor. 1 In addition, the expression levels of GPCR kinase 2 and ␤-arrestins in the particulate fraction relative to the cytosolic fraction were comparable between AT 1 Tg-AgtKO and AgtKO hearts ( Figure S4 ). Therefore, we suppose that, in the absence of Ang II, wild-type AT 1 receptor stochastically undergoes subtle and transient conformational changes, leading to partial activation of G␣ q11 -depentent signaling without inducing detectable receptor internalization. The AT 1 receptor can also stimulate G protein-independent diverse signaling pathways involving ␤-arrestins, tyrosine kinases, reactive oxygen species, and AT 1 receptor-associated proteins. 15 Further structure-function analysis will be needed to elucidate the full breadth of the molecular mechanisms and signal transduction network that mediate agonist-independent AT 1 receptor activation in the hearts.
It has been reported that the AT 1 receptor is upregulated in stressed hearts of spontaneously hypertensive rats, 25 2-kidney 1-clip renovascular hypertensive rats, 25 Tsukuba hypertensive mice, 26 and rats with myocardial infarction. 27 Furthermore, we observed that cardiac expression of the AT 1 receptor was increased Ϸ8-fold in pressure-overloaded mice after transverse aortic constriction (B max : 142.9Ϯ36.5 fmol/mg; nϭ3) compared with sham-operated mice (B max : 16.4Ϯ4.9 fmol/ mg; nϭ3). In addition, it has been reported that the AT 1 receptor is upregulated in response to low-density lipoprotein cholesterol, 28 insulin, 29 glucose, 30 progesterone, 31 and inflammatory cytokines, such as interleukin 1␣ or interleukin 6, 32, 33 in vascular cells. Therefore, it seems quite reasonable to assume that enhancement of constitutive activity of the AT 1 receptor through upregulation of receptor expression may accelerate the progression of atherosclerosis in patients with hypercholesterolemia or diabetes mellitus, especially after menopause. Further studies in animal models will be required to clarify the roles of constitutive activity of the AT 1 receptor in the pathogenesis of cardiovascular and metabolic disorders.
We also demonstrate that treatment with candesartan, inverse agonist for the AT 1 receptor, effectively prevents cardiac remodeling in AT 1 Tg-AgtKO mice. The inverse agonist activity of ARBs may provide clinical advantage of inhibiting both Ang II-dependent and -independent receptor activation and, thus, be an important pharmacological parameter defining the beneficial effects on organ protection. 3 Several ARBs are currently available for the treatment of hypertension and heart failure with reduced left ventricular ejection fraction, and their potency of inverse agonist activity differs according to the distinct chemical structure of the drug. 3 For example, the inhibitory effect of olmesartan on both constitutive activity and stretch-induced activation of the AT 1 receptor was significantly higher than that of losartan. 2 According to a recent article, 34 the use of candesartan was associated with lower all-cause mortality than the use with losartan in a Swedish registry of patients with heart failure. Although EXP3174, an active metabolite of losartan, can act as an inverse agonist, 8 it is tempting to speculate that the potent inverse agonist activity of candesartan may explain some of its association with lower mortality in patients with heart failure.
Perspectives
Blockade of the renin-angiotensin system has been shown to be beneficial in patients with hypertension, especially those with cardiovascular and metabolic complications. Our findings show that constitutive activity of the AT 1 receptor contributes to the progression of cardiac remodeling even in the absence of Ang II, when the AT 1 receptor is upregulated in the heart. Inverse agonism of ARBs provides therapeutic effects in the prevention of cardiac remodeling induced by constitutive activity of AT 1 receptor and, thus, has potential impact on long-term outcomes in patients with hypertension. Our work is the first proof-of-principle experiment, to our knowledge, on the in vivo importance of constitutive activity of a native GPCR in the pathogenesis of diseases. Beyond in vitro pharmacological tools, inverse agonists emerge as promising pharmacological candidates in treating diseases caused by enhancement of constitutive activity through upregulation of GPCRs.
Supplemental Materials and Methods
Mice, TAC operation, and transthoracic echocardiography
Mice expressing the human AGTR1a gene under the control of α-myosin heavy chain (MHC) promoter and mice deficient for Agt gene were previously described 1, 2 . We crossed AGTR1a
Tg/o mice (on the C57BL/6 background) with Agt -/-mice (on the ICR background), and then bred the resulting AGTR1a
Tg Tg/o /Agt +/-with Agt -/-mice. C57BL/6 mice were purchased from Japan SLC. Candesartan and candesartan-7H were synthesized in Takeda Pharmaceutical Co., Ltd., and administered via drinking water. For TAC operation, 10-week-old male mice were anesthetized by i.p. injection of pentobarbital (50 mg/kg), and respiration was artificially controlled with a tidal volume of 0.2 ml and a respiratory rate of 110 breaths/min. The transverse aorta was constricted with 7-0 nylon strings by ligating the aorta with splinting a blunted 27 gauge needle, which was removed after the ligation. After aortic constriction, the chest was closed and mice were allowed to recover from anesthesia. We confirmed that the magnitude of initial pressure elevation after aortic banding was identical in all groups of mice. The surgeon had no information about the mice used in this study. For evaluation of cardiac dimensions and contractility, transthoracic echocardiography was performed on conscious mice with Vevo 770 Imaging System using a 25 MHz linear probe (Visual Sonics). All protocols were approved by the Institutional Animal Care and Use Commmittee of Chiba University.
Ang II infusion and BP measurement
Ang II (Sigma-Aldrich) was dissolved in 0.9% saline. Eight-week-old C57BL/6J male mice were treated with Ang II (0.6 mg/kg/day) or vehicle for 2 weeks using an osmotic mini-pump (ALZET model 2002; Durent Corp.). The systolic and diastolic BP and pulse rates were measured in conscious mice noninvasively by a programmable sphygmomanometer (BP-98A, Softron) using the tail-cuff method.
Real-time RT-PCR analysis
Total RNA was extracted by using RNeasy Kit (Qiagen), and single-stranded cDNA was transcribed by using QuantiTect Reverse Transcription Kit (Qiagen), according to the manufacturer's protocol. We conducted quantitative real-time PCR analysis with the Universal ProbeLibrary Assays (Roche Applied Science), according to the manufacturer's instructions. Amplification conditions were initial denaturation for 10 min at 95°C followed by 45 cycles of 10 s at 95°C and 25 s at 60°C. Individual PCR products were analyzed by melting-point analysis. The expression level of a gene was normalized relative to that of Gapdh by using a comparative Ct method. The primer sequences and Universal Probe numbers were designed with the ProbeFinder software as following: Agtr1b, 
Western blot analysis and subcellular fractionation
Protein samples were fractionated with SDS-PAGE, transferred to PVDF membranes (GE Healthcare Biosciences). The blotted membranes were incubated with primary antibody, followed by horseradish peroxidase-conjugated secondary antibody (Jackson ImmunoResearch Laboratories). Immunoreactive signals were visualized using ECL Plus Western Blotting Detection System (GE Healthcare Biosciences). Following antibodies were used: rabbit polyclonal anti-Gα q/11 antibody, goat polyclonal anti-GAPDH antibody (Santa Cruz Biotechnology, Inc.), rabbit polyclonal anti-phospho-ERK1/2 antibody (Cell Signaling Techonlogy), rabbit polycloncal anti-ERK1/2 antibody (Invitrogen), rabbit polyclonal anti-AT 2 receptor antibody (Alomone Labs), mouse monoclonal anti-GRK2 antibody (Santa Cruz), and mouse monoclonal anti-β-arrestin 1/2 antibody (Santa Cruz).
For subcellular fractionation, heart samples were homogenized in lysis buffer (25 mM Tris HCl pH 7.4, 5 mM EGTA, 2 mM EDTA, 100 mM NaF, 5 mM DTT) plus protease inhibitors (Complete mini; Roche Applied Science). The lysates were centrifuged at 500 g for 20 min to pellet unbroken cells and nuclei. The supernatant was centrifuged at 100,000 g for 60 min, and the supernatant was designated as the cytosolic fraction. The pellets were then resuspended as the membrane-particulate fraction in lysis buffer with 1% Triton X-100.
Histological analysisHearts were excised, fixed immediately in 10% neutralized formalin, and embedded in paraffin. Serial sections at 5 µm were stained with Masson's trichrome for evaluation of fibrosis.
Radioligand receptor binding assayRadioligand-binding assays were performed as described previously [3] [4] [5] . The protein in membrane fraction was incubated with 100 pM 125 I-[Sar 1 , Ile 8 ] Ang II (Perkin Elmer) for 1 hr at 22℃. Binding reaction was terminated by filtering the incubation mixture through Whatman GF/C glass filters (GE healthcare Biosciences), and the residues were extensively washed further with binding buffer. The bound ligand fraction was determined from the counts per minute (cpm) remaining on the membrane. Binding kinetics values were determined with the LIGAND computer program (Elsevier-Biosoft), as previously described [3] [4] [5] .
Statistics
All data are presented as means + SEM. Two-group comparison was analyzed by unpaired 2-tailed Student's t test, and multiple-group comparison was performed by one-way ANOVA followed by the Fisher`s PLSD test for comparison of means. A probability value of P < 0.05 was considered to be statistically significant. Figure S2 6 Figure S2 . Systolic BP in AT 1 Tg mice treated with vehicle (n = 9), AgtKO mice treated with vehicle (n = 6), AT 1 Tg-AgtKO mice treated with vehicle (n = 6), candesartan cilexetil (Can) (1 mg/kg/day, n = 8) or candesartan-7H (Can-7H) (1 mg/kg/day, n = 5 or 20 mg/kg/day, n = 5). BP was measured in 20-week-old mice after the treatment for 14 weeks. Data are presented as mean + SEM. **P < 0.01 versus AgtKO mice. 
